Pharmaceutical Executive Daily: FDA Approves Breztri

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers two significant deals, Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move to acquire Japanese OTC manufacturer Matsumoto Pharmaceutical, the FDA approves AstraZeneca's Breztri Aerosphere as the first and only single-inhaler triple-combination maintenance therapy for asthma in patients 12 and older, and a new Pharmaceutical Executive feature examines why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.

Two pharma acquisitions are making headlines this week. In the larger of the two, Sun Pharmaceutical Industries has entered a definitive agreement to acquire Organon for $14.00 per share in an all-cash transaction valued at $11.75 billion, a deal that would make the combined company one of the top 25 global pharmaceutical firms In a separate transaction, IMG Pharmaceutical, a subsidiary of Japan's IMG Japan, has announced plans to acquire Matsumoto Pharmaceutical, a Kansai-based OTC manufacturer founded in 1948 with more than 50 drug approvals across digestive, respiratory, dermatological, and metabolic health categories.

The FDA has approved Breztri Aerosphere as the first and only single-inhaler triple-combination maintenance therapy for asthma in adult and pediatric patients 12 years of age and older. The approval is based on Phase III data which demonstrated statistically significant and clinically meaningful improvements in lung function versus dual ICS/LABA therapy, with no new safety signals identified in either study.

Finally, a new feature by Damien O'Brien of IDA Ireland traces how Ireland evolved from an early foreign direct investment destination in the 1960s into one of the world's most consequential pharmaceutical manufacturing locations, now home to approximately 50 API and drug product manufacturing sites, nine of the top ten global biopharma companies, and a compliance track record that the article describes as consistently among the strongest of any jurisdiction measured by FDA inspection outcomes.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.